RARE
NASDAQUltragenyx Pharmaceutical Inc.
News · 26 weeks68+267%
2026-03-012026-08-23
Mix2190d
- Other7(33%)
- Insider6(29%)
- SEC Filings4(19%)
- Earnings3(14%)
- Leadership1(5%)
Latest news
25 items- PRUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,984 restricted stock units of the company’s common stock to 23 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)
- SECUltragenyx Pharmaceutical Inc. filed SEC Form 8-K: Other Events8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)
- PRUltragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to reduce the burden of care associated with GSDIa Ultragenyx received a Priority Review Voucher upon approval Ultragenyx to host conference call on 8/19/26 at 6:00 p.m. Eastern Time NOVATO, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). "Th
- SECSEC Form SCHEDULE 13G filed by Ultragenyx Pharmaceutical Inc.SCHEDULE 13G - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)
- SECSEC Form SCHEDULE 13G filed by Ultragenyx Pharmaceutical Inc.SCHEDULE 13G - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)
- SECUltragenyx Pharmaceutical Inc. filed SEC Form 8-K: Other Events8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)
- SECSEC Form SCHEDULE 13G filed by Ultragenyx Pharmaceutical Inc.SCHEDULE 13G - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)
- SECUltragenyx Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)
- PRUltragenyx Reports Second Quarter 2026 Financial Results and Corporate UpdateSecond quarter total revenue of $214 million, Crysvita® revenue of $156 million and Dojolvi® revenue of $27 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expenses to be flat to slightly down versus 2025; remain on path to profitability in 2027 Catalysts in second half of 2026 include two PDUFA dates and pivotal data readout from GTX-102 Phase 3 Aspire study for Angelman syndrome NOVATO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genet
- INSIDEREVP and Chief Legal Officer Parschauer Karah Herdman sold $47,348 worth of shares (1,900 units at $24.92), decreasing direct ownership by 2% to 92,562 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDERChief Financial Officer Horn Howard sold $117,024 worth of shares (4,696 units at $24.92), decreasing direct ownership by 5% to 96,295 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- PRUltragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate UpdateNOVATO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, August 4, 2026, to discuss its financial results and corporate update for the quarter ending June 30, 2026. The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmaceutic
- PRUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 65,886 restricted stock units of the company’s common stock to 39 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
- INSIDERChief Financial Officer Horn Howard sold $155,645 worth of shares (4,698 units at $33.13), decreasing direct ownership by 4% to 100,991 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- PRCalidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of DirectorsSAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 17, 2026. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders has an exceptional track record in developing new technologies," said Calidi Chairman of the Board Jim Schoeneck. "We believe her deep expertise in the clinical development of novel therapeutics will be highly valuable as Calidi advances CLD-401 and its RedTail platform into
- PRUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company’s common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
- INSIDERDirector Sanders Corazon (Corsee) D. sold $50,100 worth of shares (2,000 units at $25.05), decreasing direct ownership by 9% to 21,095 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDEREVP and Chief Legal Officer Parschauer Karah Herdman sold $46,753 worth of shares (1,899 units at $24.62), decreasing direct ownership by 2% to 94,462 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- SECSEC Form S-8 filed by Ultragenyx Pharmaceutical Inc.S-8 - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)
- PRUltragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare ConferenceNOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 PM ET. The live and archived webcast of the panel will be accessible from the company's website at https://ir.ultragenyx.com/events-presentations. About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical comp
- INSIDERChief Financial Officer Horn Howard sold $110,602 worth of shares (4,653 units at $23.77), decreasing direct ownership by 4% to 105,689 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- PRUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 17,567 restricted stock units of the company's common stock to 11 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). T
- INSIDERDirector Fust Matthew K was granted 7,751 shares, increasing direct ownership by 30% to 33,696 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDERDirector Suliman Shehnaaz was granted 7,751 shares and sold $144,189 worth of shares (5,740 units at $25.12), increasing direct ownership by 8% to 27,951 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
- INSIDERDirector Ray Amrit was granted 7,751 shares, increasing direct ownership by 33% to 31,116 units (SEC Form 4)4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)
RARE FAQ
7 questionsWhat does Ultragenyx Pharmaceutical Inc. do?
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation...Where does RARE stock trade?
Ultragenyx Pharmaceutical Inc. (RARE) is listed on NASDAQ.What sector and industry is RARE in?
Ultragenyx Pharmaceutical Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ultragenyx Pharmaceutical Inc. go public?
Ultragenyx Pharmaceutical Inc. (RARE) completed its IPO in 2014.What are analysts saying about RARE?
Ultragenyx Pharmaceutical Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral with a $2500.00 price target on 2026-03-24. Recent price targets cluster around $2500.00.What companies are similar to RARE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RARE side-by-side with any of them on Quantisnow.How can I track RARE on Quantisnow?
Quantisnow aggregates Ultragenyx Pharmaceutical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RARE to receive live email and push alerts on every new disclosure.